Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · IEX Real-Time Price · USD
236.16
+10.67 (4.73%)
At close: May 31, 2024, 4:00 PM
220.00
-16.16 (-6.84%)
After-hours: May 31, 2024, 7:56 PM EDT
Madrigal Pharmaceuticals Employees
Madrigal Pharmaceuticals had 376 employees on December 31, 2023. The number of employees increased by 284 or 308.70% compared to the previous year.
Employees
376
Change (1Y)
284
Growth (1Y)
308.70%
Revenue / Employee
n/a
Profits / Employee
-$1,181,582
Market Cap
5.03B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 376 | 284 | 308.70% |
| Dec 31, 2022 | 92 | 21 | 29.58% |
| Dec 31, 2021 | 71 | 29 | 69.05% |
| Dec 31, 2020 | 42 | 13 | 44.83% |
| Dec 31, 2019 | 29 | 12 | 70.59% |
| Dec 31, 2018 | 17 | 9 | 112.50% |
| Dec 31, 2017 | 8 | 0 | - |
| Dec 31, 2016 | 8 | -2 | -20.00% |
| Dec 31, 2015 | 10 | -100 | -90.91% |
| Dec 31, 2014 | 110 | -24 | -17.91% |
| Dec 31, 2013 | 134 | 10 | 8.06% |
| Dec 31, 2012 | 124 | 2 | 1.64% |
| Dec 31, 2011 | 122 | 10 | 8.93% |
| Dec 31, 2010 | 112 | -15 | -11.81% |
| Dec 31, 2009 | 127 | -2 | -1.55% |
| Dec 31, 2008 | 129 | -46 | -26.29% |
| Dec 31, 2007 | 175 | 29 | 19.86% |
| Dec 31, 2006 | 146 | 28 | 23.73% |
| Jan 12, 2005 | 118 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Option Care Health | 7,802 |
| Merit Medical Systems | 6,950 |
| Stevanato Group | 5,634 |
| Inspire Medical Systems | 1,011 |
| Doximity | 977 |
| Ionis Pharmaceuticals | 927 |
| Apellis Pharmaceuticals | 702 |
| ImmunityBio | 628 |
MDGL News
- 26 days ago - Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 5 weeks ago - Madrigal Statement on the Passing of Dr. Stephen Harrison - GlobeNewsWire
- 6 weeks ago - Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering - GlobeNewsWire
- 2 months ago - Madrigal Pharmaceuticals Announces Proposed Public Offering - GlobeNewsWire
- 2 months ago - Madrigal Pharma surges on FDA nod to first drug for fatty liver disease NASH - Reuters
- 2 months ago - FDA approves Madrigal Pharmaceuticals drug as first treatment for common NASH liver disease - CNBC
- 2 months ago - Madrigal Pharmaceuticals gets first FDA approval for drug targeting liver disease MASH - Market Watch